Form 4: Vera Therapeutics COO Granted Equity Awards

Vera Therapeutics' Chief Operating Officer, David Lee Johnson, was granted 20,000 restricted stock units and 40,000 stock options as part of a pre-planned equity incentive.

Summary

• David Lee Johnson, Chief Operating Officer of Vera Therapeutics, Inc. (VERA), was granted equity awards.
• On February 4, 2026, Johnson acquired 20,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest in four equal annual installments, with 1/4th vesting on February 20, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Additionally, on February 4, 2026, Johnson was granted 40,000 stock options with an exercise price of $42.74 and an expiration date of February 3, 2036.
• These stock options will vest monthly, with 1/48th vesting on March 4, 2026, and 1/48th on the same day of each subsequent month, also subject to continuous service.
• Following these transactions, Johnson beneficially owns 48,306 shares of Class A Common Stock and 40,000 derivative securities (stock options).
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of restricted stock units and stock options aligns the Chief Operating Officer's interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options incentivize continuous service and performance over several years.
• The transactions were pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to equity compensation.

Negatives

• No immediate negative aspects are apparent from this Form 4 filing, which primarily reports equity grants.

Risks

• The value of the granted equity awards is subject to the future performance of Vera Therapeutics' stock price.
• Vesting of the awards is contingent on the reporting person's continuous service, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The filing outlines future vesting schedules for both restricted stock units and stock options, extending through February 2030 for RSUs and March 2026 onwards for monthly option vesting, contingent on continuous service. This indicates a long-term incentive structure for the Chief Operating Officer.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing, which is a transactional report.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Operating Officer are a standard practice in the biotechnology and pharmaceutical industry. These grants, particularly those with multi-year vesting schedules, are designed to retain talent, align executive incentives with long-term company performance, and encourage strategic decision-making that benefits shareholders. This practice is common among peers in the biotech sector, where long development cycles necessitate sustained executive commitment.

Comparison to Industry Standards

• The structure of multi-year vesting for both RSUs and stock options is consistent with compensation practices observed at comparable biotech firms, such as those in the mid-cap range with active R&D pipelines.
• The use of a Rule 10b5-1(c) plan for these transactions reflects a commitment to transparent and pre-scheduled equity compensation, a best practice in corporate governance.
• The exercise price of $42.74 for the stock options would typically be set at the fair market value on the grant date, which is standard for incentive stock options across industries.

Stakeholder Impact

• Shareholders: The grants align executive interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Vesting of 1/48th of stock options monthly, starting March 4, 2026.
• Vesting of 1/4th of RSUs annually, starting February 20, 2027, through February 20, 2030.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice aimed at aligning management incentives with long-term company performance. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, David Lee Johnson, Chief Operating Officer, 10b5-1 Plan